康华生物
(300841)
| 流通市值：92.41亿 | | | 总市值：100.97亿 |
| 流通股本：1.19亿 | | | 总股本：1.30亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 840,062,581.82 | 483,918,966.75 | 137,942,758.51 | 1,431,876,597.94 |
| 营业收入 | 840,062,581.82 | 483,918,966.75 | 137,942,758.51 | 1,431,876,597.94 |
| 二、营业总成本 | 613,116,128.08 | 348,216,470.57 | 112,232,733.05 | 875,179,262.72 |
| 营业成本 | 64,779,534.41 | 34,926,612.13 | 7,686,111.19 | 83,007,303.55 |
| 税金及附加 | 6,102,420.62 | 4,653,615.17 | 533,949.02 | 10,278,938.01 |
| 销售费用 | 379,851,048.58 | 204,346,644.01 | 55,981,177.56 | 547,123,711.92 |
| 管理费用 | 82,608,370.51 | 52,158,843.58 | 23,438,576.84 | 111,272,410.38 |
| 研发费用 | 83,001,056.64 | 54,878,685.63 | 25,052,456.67 | 132,051,132.76 |
| 财务费用 | -3,226,302.68 | -2,747,929.95 | -459,538.23 | -8,554,233.9 |
| 其中:利息费用 | 2,858,721.58 | 2,043,447.42 | 1,115,590.59 | 5,375,722.11 |
| 其中:利息收入 | 6,038,610.81 | 4,736,721.41 | 1,516,930.58 | 12,280,125.92 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,897,619.2 | 1,897,619.2 | 106,031.53 | -59,726,140.81 |
| 加:投资收益 | 3,010,488.97 | 109,780.81 | 109,780.81 | 891,245.73 |
| 资产处置收益 | -8,912.45 | -8,912.45 | - | -1,794,548.96 |
| 资产减值损失(新) | -7,687,974.43 | -72,708.38 | -80,892.18 | -1,629,924.78 |
| 信用减值损失(新) | -4,320,450.39 | -13,694,496.1 | -6,364,268.12 | -30,142,222.91 |
| 其他收益 | 1,863,267.02 | 1,604,355.65 | 583,734.28 | 2,988,010.07 |
| 四、营业利润 | 221,700,491.66 | 125,538,134.91 | 20,064,411.78 | 467,283,753.56 |
| 加:营业外收入 | - | - | - | 6,270.29 |
| 减:营业外支出 | 46,493.28 | 40,240.61 | 6,613.79 | 266,636.35 |
| 五、利润总额 | 221,653,998.38 | 125,497,894.3 | 20,057,797.99 | 467,023,387.5 |
| 减:所得税费用 | 32,543,277.62 | 10,977,313.81 | -650,796.71 | 68,371,464.41 |
| 六、净利润 | 189,110,720.76 | 114,520,580.49 | 20,708,594.7 | 398,651,923.09 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 189,110,720.76 | - | 20,708,594.7 | 398,651,923.09 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 189,110,720.76 | 114,520,580.49 | 20,708,594.7 | 398,651,923.09 |
| 扣除非经常损益后的净利润 | 183,318,264.19 | 111,553,521.15 | 20,092,445.93 | 457,495,046.29 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.46 | 0.88 | 0.16 | 3.03 |
| (二)稀释每股收益 | 1.46 | 0.88 | 0.16 | 3.03 |
| 九、综合收益总额 | 189,110,720.76 | 114,520,580.49 | 20,708,594.7 | 398,651,923.09 |
| 归属于母公司股东的综合收益总额 | 189,110,720.76 | 114,520,580.49 | 20,708,594.7 | 398,651,923.09 |
| 公告日期 | 2025-10-17 | 2025-08-26 | 2025-04-19 | 2025-04-19 |
| 审计意见(境内) | | | | 标准无保留意见 |